Rajib Bhattacharya is an Endocrinology/Metabolic physician affiliated with Truman Medical Center. OpenAlex indexes 89 publications with 957 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2301 Holmes St
Kansas City, MO 641082640
Telephone
816-404-4070Provider last certified this registry record 20 Apr 2022.
Clinical trials
- Hypovitaminosis D and an Inadequate PTH Response in Chronic Liver Disease Patients
Sponsor: Rajib Bhattacharya, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ascendis Pharma Endocrinology IncProgram year202520 payments$15,004openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20252 payments
- Amgen Inc.Program year20245 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
42.6%SGLT2 inhibitor12.3%Farxiga51%Jardiance50%Part D≥17 patientsGLP-1 receptor agonist11.2%Trulicity72%Ozempic28%Part D<11 patients+ 3 more classes in this area
Hormonal (systemic)
24%l-Thyroxine22.1%Levothyroxine Sodium90%Synthroid10%Part D<11 patientsThyroid Hormone Synthesis Inhibitor1.8%Methimazole100%Part D<11 patientsCardiovascular
22.5%Statin7.3%Atorvastatin Calcium75%Rosuvastatin Calcium25%Part D<11 patientsAngiotensin receptor blocker (ARB)5.5%Losartan Potassium100%Part D≥13 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-term use of semaglutide and risk of diabetic retinopathy progression
Endocrine and Metabolic Science
2024 - PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
Journal of the Endocrine Society
2022
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”